Luscan-Lumish Syndrome: Comprehensive Disease Characteristics Report

Disease Name: Luscan-Lumish Syndrome (LLS) MONDO ID: MONDO:0014916 OMIM (phenotype): #616831 · OMIM (gene): 612778 · Orphanet: ORPHA:457485 Category: Genetic (autosomal dominant overgrowth + neurodevelopmental disorder) Causal Gene: SETD2* (HGNC:18420; NCBI Gene 29072; UniProt Q9BYW2; chromosome 3p21.31)

Summary

Luscan-Lumish syndrome (LLS) is an ultra-rare, autosomal-dominant overgrowth and neurodevelopmental disorder caused by heterozygous, near-universally de novo loss-of-function (LoF) variants in SETD2, the sole somatic histone H3 lysine-36 trimethyltransferase (H3K36me3). First delineated by Lumish and colleagues in 2015 in a girl with autism, intellectual disability, seizures, Chiari I malformation, and macrocephaly carrying a de novo frameshift variant (c.2028delT, p.P677LfsX19), the condition has since been reported in approximately 50 patients worldwide. The core clinical picture combines postnatal overgrowth — macrocephaly (near-universal), tall/advanced stature, and obesity (~50%) — with a highly penetrant neurodevelopmental and behavioral phenotype: intellectual disability (~83%), autism spectrum disorder (~89%), and behavioral difficulties (~100%), often with aggressive outbursts (~83%), speech and motor delay, and advanced carpal (bone) ossification. LLS is classified within the "Sotos-like" family of epigenetic overgrowth syndromes.

The molecular basis is dual. SETD2 is a "chromatocytoskeletal" dual-function methyltransferase: it writes H3K36me3 — essential for transcriptional fidelity (suppression of cryptic transcription), splicing, DNA repair, and genomic stability — and it also methylates α-tubulin at Lys40 (α-TubK40me3) and actin, linking it to microtubule/cytoskeletal function. Haploinsufficiency therefore simultaneously perturbs chromatin regulation and cytoskeletal dynamics. Model-organism work directly ties both arms to the phenotype: the H2A.z–Setd2–H3K36me3 axis drives embryonic cortical neurogenesis (via Nkx2-4), and α-TubK40me3 is required for neuronal polarization and migration in the developing cortex, as well as for mitotic-spindle integrity.

Diagnosis is molecular — trio whole-exome or whole-genome sequencing, or overgrowth/intellectual-disability multigene panels — now reinforced by a distinctive SETD2 DNA-methylation episignature (EpiSign) that supports diagnosis and reclassifies variants of uncertain significance. Importantly, a genotype–phenotype dichotomy exists at the same locus: recurrent de novo missense variants at codon 1740 produce clinically distinct, more severe, growth-restricted disorders — Rabin-Pappas syndrome (RAPAS, p.Arg1740Trp; MIM 620155) and autosomal-dominant intellectual developmental disorder 70 (MRD70, p.Arg1740Gln) — implying a non-LoF (e.g., gain-of-function or altered epigenetic-regulation) mechanism rather than simple haploinsufficiency. No disease-specific or curative therapy exists; management is entirely supportive and multidisciplinary.

1. Disease Information

LLS is a monogenic overgrowth-with-intellectual-disability syndrome in the "Sotos-like" group. It is characterized by "postnatal overgrowth, macrocephaly, obesity, speech delay, and advanced carpal ossification" together with a strongly penetrant neurodevelopmental/behavioral profile (PMID: 31643139).

Key identifiers: - OMIM (phenotype): #616831 (Luscan-Lumish syndrome) - OMIM (gene): 612778 (SETD2) - Orphanet: ORPHA:457485 - MONDO: MONDO:0014916 - MeSH / ICD: No dedicated MeSH heading or specific ICD-10 code; captured under broad codes for congenital malformation syndromes / intellectual disability. ICD-11 would map to a rare-syndrome/developmental-anomaly category. - HGNC: HGNC:18420 (SETD2*)

Synonyms / alternative names: SETD2-related overgrowth syndrome; SETD2-related disorder; intellectual disability, autosomal dominant, with overgrowth (historical descriptions). Note that "SETD2-related disorders" is an umbrella now spanning three nosologically distinct entities: LLS, MRD70, and RAPAS (PMID: 37372360).

Source of information: Aggregated disease-level knowledge from published case reports/series (~50 patients) and mechanistic/model-organism studies — not from a large EHR cohort.

2. Etiology

Primary cause (genetic). LLS is caused by heterozygous, intragenic loss-of-function variants in SETD2. Constitutional SETD2 mutations are "intragenic loss-of-function variants with truncating (69%) and missense (31%) mutations" (PMID: 31643139). The founding case carried a de novo frameshift: "a de novo c.2028delT (P677LfsX19) mutation in the SET domain-containing protein 2 (SETD2) gene, predicted to be gene-damaging" (PMID: 26084711).

Genetic risk factors. The causal event is the SETD2 LoF variant itself, arising de novo; there are no known susceptibility loci or modifier genes established for LLS. Large 3p21.31 deletions encompassing SETD2 can reproduce part of the phenotype (PMID: 27385966).

Environmental risk factors / protective factors / gene–environment interactions. None established. As a de novo dominant Mendelian disorder, LLS has no recognized environmental, lifestyle, or infectious contribution, and no protective alleles or GxE interactions have been reported. Advanced paternal age is a general (non-specific) consideration for de novo single-nucleotide variants but is not documented specifically for LLS.

3. Phenotypes

Per-phenotype frequencies derive chiefly from the Marzin (2019) cohort (n=13): "neurodevelopmental disorders are common such as intellectual disability (83%), autism spectrum disorders (89%), and behavioral difficulties (100%) with aggressive outbursts (83%). A variety of features such as joint hypermobility (29%), hirsutism (33%), and naevi (50%) were also reported" (PMID: 31643139).

Severity/progression: Variable expressivity, ranging from a mild adult overgrowth presentation "without neurological symptoms" (PMID: 33248444) to classic ID/ASD/overgrowth. Core neurodevelopmental features are generally stable (non-progressive) but lifelong. A rare/unusual manifestation, bilateral condylar hyperplasia, has been reported as part of the expanding phenotype (PMID: 40892041).

Quality-of-life impact: Driven mainly by ID, ASD, and behavioral difficulties (impact on communication, education, independence, and family/caregiver burden). Formal QoL instrument data (EQ-5D/SF-36/PROMIS) are not published for LLS.

4. Genetic / Molecular Information

• Causal gene: SETD2 (SET domain-containing 2), HGNC:18420, OMIM *612778, locus 3p21.31; encodes the sole somatic H3K36 trimethyltransferase.
• Variant classification (ACMG/AMP): Pathogenic/likely-pathogenic LoF variants; the SETD2 episignature helps reclassify VUS (PMID: 40104911).
• Variant types: Truncating (~69%: frameshift, nonsense, splice-site) and missense (~31%) (PMID: 31643139). Representative: c.2028delT (p.P677LfsX19) (PMID: 26084711).
• Allele frequency: Pathogenic variants are private/de novo; absent from population databases (gnomAD) — consistent with strong SETD2 constraint against LoF.
• Somatic vs germline: LLS variants are germline (constitutional), de novo. Somatic SETD2 LoF is a separate, well-established oncogenic event (renal cell carcinoma, leukemia, glioma).
• Functional consequence: Loss of function / haploinsufficiency for LLS. By contrast, codon-1740 missense variants likely act through a non-LoF mechanism (PMID: 32710489).
• Modifier genes: None established.
• Epigenetic information: A distinctive DNA-methylation episignature characterizes LLS/SETD2-related disorders and is detectable by EpiSign (PMID: 40104911).
• Chromosomal abnormalities: Interstitial 3p21.31 deletions encompassing SETD2 can produce overlapping features (developmental delay, ID, dysmorphism) (PMID: 27385966).

Genotype–phenotype dichotomy at codon 1740: Rabin (2020) identified 15 individuals with de novo codon-1740 variants — p.Arg1740Trp (n=12) → RAPAS (microcephaly, profound ID, multi-organ anomalies; MIM 620155) and p.Arg1740Gln (n=3) → MRD70 (moderate-severe ID). "The phenotype of Group 1 includes microcephaly, profound intellectual disability, congenital anomalies affecting several organ systems, and similar facial features," and "the clinical features seen in individuals with variants affecting codon 1740 are more severe suggesting an alternative mechanism, such as gain of function, effects on epigenetic regulation, or posttranslational" modification (PMID: 32710489).

5. Environmental Information

No environmental, lifestyle, or infectious factors are known to cause or trigger LLS. It is a monogenic de novo dominant disorder. Obesity, when present, is a phenotypic feature partly amenable to lifestyle/nutritional management rather than an etiologic exposure (PMID: 29681085). No infectious agents apply.

6. Mechanism / Pathophysiology

Central node — SETD2 dual enzymatic activity. SETD2 "is a dual-function methyltransferase for histones and microtubules and plays an important role for transcriptional regulation, genomic stability, and cytoskeletal functions" (PMID: 32710489); it has "chromatocytoskeletal activity, methylating both histones and microtubules" (PMID: 32620673).

Chromatin arm (H3K36me3). As the sole somatic H3K36me3 writer, SETD2 loss reduces transcriptional fidelity (allowing cryptic transcription), impairs co-transcriptional splicing, and compromises DNA repair and genomic stability. In the brain, the H2A.z–Setd2–H3K36me3 axis drives neurogenesis: "H2A.z regulates embryonic neurogenesis by targeting Nkx2-4 through interaction with Setd2, thereby promoting H3K36me3 modification to activate the transcription of Nkx2-4" (PMID: 29294103).

Cytoskeletal arm (α-TubK40me3). SETD2 methylates α-tubulin at Lys40; this mark is enriched in mouse cortex at E14–E16 and is required for neuronal migration: "Knockdown of α-tubulin methyltransferase SETD2 at E14 leads to the defects in neuronal migration, which could be restored by overexpressing either a cytoplasm-localized SETD2 truncation or α-TubK40me3-mimicking mutant" (PMID: 34226540). Loss also degrades spindle integrity: "SETD2 is a dual-function methyltransferase important for methylation of histone H3 at lysine 36 and α-tubulin in spindle microtubules" (PMID: 41827754), producing chromatin bridges, micronuclei, and aneuploidy. The α-TubK40me3 regulatory triad comprises writer SETD2, reader PBRM1, and eraser KDM4A (PMID: 41171906); a Drosophila Set2 E741Q model confirms spindle defects (PMID: 38290049).

Candidate overgrowth mechanism. In one LLS case, patient cells "showed enhanced tyrosine phosphorylation and transcriptional activity of signal transducer and activator of transcription 5b (STAT5b) and increased IGF-1 expression induced by GH" (PMID: 33248444), implicating a GH→STAT5b→IGF-1 axis in postnatal overgrowth (single case; not yet generalized).

Suggested ontology terms: - GO (BP): histone H3-K36 trimethylation (GO:0010452); DNA repair (GO:0006281); microtubule cytoskeleton organization (GO:0000226); mitotic spindle organization (GO:0007052); neuron migration (GO:0001764); regulation of transcription elongation. - GO (CC): nucleus (GO:0005634); chromatin (GO:0000785); microtubule (GO:0005874); mitotic spindle (GO:0072686). - CL: neuron (CL:0000540); cortical projection neuron; radial glial/neural progenitor cell (CL:0000047). - CHEBI: S-adenosyl-L-methionine (CHEBI:15414, methyl donor).

7. Anatomical Structures Affected

• Organ/system level: Central nervous system (primary) — cerebral cortex; brain (UBERON:0000956, UBERON:0000955), reflected in ID, ASD, seizures, and posterior-fossa Chiari I malformation. Skeletal system — macrocephaly, tall stature, advanced carpal ossification, rare condylar hyperplasia. Integument — naevi, hirsutism. Endocrine/growth axis — candidate GH/IGF-1 involvement.
• Tissue/cell level: Nervous tissue (cortical neurons, neural progenitors CL:0000047); connective tissue laxity (joint hypermobility).
• Subcellular level: Nucleus/chromatin (H3K36me3) and microtubule/mitotic spindle (α-TubK40me3).
• Localization/lateralization: Bilateral/systemic; no lateralization (condylar hyperplasia notably reported as bilateral, PMID: 40892041).

8. Temporal Development

• Onset: Congenital-to-pediatric; overgrowth is characteristically postnatal (not prenatal). Developmental delay and behavioral features emerge in early childhood.
• Progression: Chronic, lifelong; core neurodevelopmental features are generally stable/non-progressive. No relapsing-remitting course; not a repeat-expansion disorder (no genetic anticipation).
• Critical periods: Embryonic cortical neurogenesis and neuronal migration (mouse E14–E16 equivalents) represent the mechanistic windows of vulnerability.

9. Inheritance and Population

• Epidemiology: Ultra-rare — ~50 reported patients (PMID: 40104911); Orphanet prevalence <1/1,000,000 (ORPHA:457485). Precise incidence unknown.
• Inheritance: Autosomal dominant; near-universally de novo. Chen (2021) "manually curate[d] 17 SETD2 de novo variants in 17 individuals from published literature" (PMID: 33766796).
• Penetrance/expressivity: High penetrance with variable expressivity, from mild (no neurological symptoms, PMID: 33248444) to classic severe.
• Recurrence risk: Low for parents of an affected child (de novo), with a residual caveat for gonadal mosaicism.
• Founder effects / consanguinity / carrier frequency: None established; not a recessive/carrier disorder.
• Demographics: No ethnic predilection, geographic clustering, or clear sex bias; both sexes affected.

10. Diagnostics

• Recommended approach: Molecular confirmation of a heterozygous pathogenic/likely-pathogenic SETD2 variant.
• Sequencing: Trio whole-exome (WES) or whole-genome (WGS) sequencing; overgrowth/intellectual-disability multigene panels (which include SETD2 alongside NSD1, EZH2, NFIX, DNMT3A, PTEN, etc.). Macrocephaly/ASD panels have detected pathogenic variants in such cohorts (PMID: 40282429).
• Chromosomal microarray (CMA): Detects 3p21.31 deletions encompassing SETD2 (PMID: 27385966).
• Epigenomic diagnostics: The SETD2 EpiSign DNA-methylation episignature supports diagnosis and VUS reclassification — "DNA methylation study by EpiSign assay confirmed the presence of an episignature profile compatible with SETD2-related disorders" (PMID: 40104911).
• Supportive workup: Growth charts (macrocephaly/tall stature), skeletal survey (advanced bone age), brain MRI (Chiari I), EEG if seizures, developmental/ASD assessment.
• Differential diagnosis: Other Sotos-like epigenetic overgrowth syndromes — Sotos (NSD1), Weaver (EZH2), Malan (NFIX), Tatton-Brown-Rahman (DNMT3A), Beckwith-Wiedemann (11p15 imprinting), and PTEN hamartoma tumor syndrome. LLS is explicitly placed here: "The SETD2 gene encoding a H3K36 trimethyltransferase is implicated in Sotos-like syndrome" (PMID: 31643139).
• Screening: No newborn or carrier screening (de novo dominant); molecular testing is diagnostic, not screening.

11. Outcome / Prognosis

• Survival/mortality: Life expectancy is not clearly reduced in classical LLS; no disease-specific mortality data published.
• Morbidity/function: Driven by ID, ASD, and behavioral difficulties affecting communication, education, independence, and caregiver burden; obesity and Chiari I add complications.
• Disease course: Chronic, lifelong, generally stable neurodevelopmental features.
• Tumor risk (uncertain): SETD2 is a canonical tumor suppressor — "SETD2 is the only known enzyme that catalyzes H3K36me3 in somatic cells and is implicated in tumor suppression across multiple cancer types" (PMID: 40948406) — and a constitutional multi-tumor case exists, prompting discussion that "given the implication of somatic SETD2 variants in benign and malignant tumors, the implication of these SETD2 constitutional variants in tumorigenesis is discussed" (PMID: 40104911). However, classical LLS cohorts have not established elevated cancer risk, and surveillance is not standardized.
• Prognostic factors: Variant type/position may influence severity (LoF → LLS overgrowth; codon-1740 → severe growth-restricted RAPAS/MRD70).

12. Treatment

There is no disease-specific or curative therapy; management is supportive and multidisciplinary.

• Developmental/rehabilitative: Early intervention; speech, occupational, and physical therapy (NCIT rehabilitation-intervention terms).
• Behavioral/ASD: Behavioral therapy; pharmacologic management of aggression when indicated.
• Neurological: Anti-seizure medication for epilepsy; neurosurgical evaluation for symptomatic Chiari I malformation.
• Metabolic: Obesity prevention/nutritional management — "prevention of obesity should be an important point of attention for patients diagnosed with a SETD2-related overgrowth syndrome" (PMID: 29681085).
• Advanced/experimental therapeutics: No gene, RNA-based, cell, or targeted therapies are available or in clinical trials for LLS.
• Pharmacogenomics: No LLS-specific pharmacogenomic guidance.

13. Prevention

• Primary prevention: Not applicable for a de novo dominant disorder.
• Genetic counseling: Convey typically low recurrence risk (with a caveat for possible parental gonadal mosaicism). Prenatal or preimplantation genetic testing is possible when a familial variant is known.
• Secondary/tertiary prevention: Developmental surveillance, obesity prevention, and management of complications (seizures, Chiari I).
• Screening: No population or newborn screening; cascade testing generally not applicable.

14. Other Species / Natural Disease

• Orthologs: SETD2 is highly conserved — mouse Setd2, zebrafish setd2, Drosophila Set2, yeast Set2.
• Natural disease: No well-characterized naturally occurring animal equivalent of LLS is documented (no established OMIA entry); disease relevance is through engineered models.
• Comparative biology: The H3K36me3 methyltransferase function is deeply conserved: in zebrafish "Setd2 is the only enzyme that catalyzes histone H3 lysine 36 trimethylation (H3K36me3) on virtually all actively transcribed protein-coding genes" (PMID: 33088589); tumor-suppressor and spindle functions are conserved from Drosophila (PMID: 38290049) to mammals.
• Zoonotic/transmission: Not applicable (genetic disorder).

15. Model Organisms

Model characteristics / limitations: Constitutive knockouts are embryonic lethal and cannot model the heterozygous adult phenotype; most models isolate one mechanistic arm (chromatin or cytoskeleton); behavioral and overgrowth features are not yet co-recapitulated in a single dose-accurate mammalian model. Resources: MGI (Setd2), ZFIN (setd2), FlyBase (Set2).

Mechanistic Model / Interpretation

Heterozygous de novo SETD2 loss-of-function variant
 (truncating ~69% / missense ~31%)
              |
     ~50% reduction in SETD2 dosage
              |
┌─────────────────────┴──────────────────────┐
│                                             │
   NUCLEAR / CHROMATIN ARM                    CYTOSKELETAL ARM
   ↓ H3K36me3                                 ↓ α-tubulin K40me3
   • transcription fidelity ↓                 • neuronal polarization ↓
   • cryptic transcription ↑                  • neuronal MIGRATION ↓
   • splicing dysregulation                   • mitotic spindle integrity ↓
   • DNA repair / genomic stability ↓         • aneuploidy / micronuclei ↑
│                                             │
│  H2A.z–Setd2–H3K36me3 → Nkx2-4              │  (writer SETD2 /
│  → cortical neurogenesis                    │   reader PBRM1 /
│                                             │   eraser KDM4A)
└─────────────────────┬──────────────────────┘
              |
   Impaired cortical neurodevelopment + dysregulated growth signaling
(candidate GH → STAT5b → IGF-1 axis in some patients)
              |
   ┌──────────────────────────┴───────────────────────────┐
   │ NEURODEVELOPMENTAL: ID (~83%), ASD (~89%),            │
   │   behavior (~100%), speech/motor delay, seizures      │
   │ OVERGROWTH: macrocephaly (~all), tall stature/         │
   │   obesity (~50%), advanced carpal ossification        │
   └───────────────────────────────────────────────────────┘

Upstream → downstream logic: The SETD2 LoF variant is the single upstream trigger. Its two enzymatic outputs (H3K36me3 and α-TubK40me3) act as parallel intermediate nodes. The chromatin arm predominantly explains transcriptional/growth dysregulation and neurogenesis defects; the cytoskeletal arm explains neuronal migration and mitotic phenotypes. Both converge on the developing cerebral cortex, yielding the combined overgrowth-plus-neurodevelopmental picture. The codon-1740 growth-restricted disorders (RAPAS/MRD70) at the same locus arise via a distinct (non-LoF) mechanism, showing that dosage and mechanism dictate divergent outcomes.

Evidence Base

Limitations and Knowledge Gaps

1. Small sample size. All clinical conclusions rest on ~50 reported patients (largest single cohort n=13); frequency estimates carry wide confidence intervals and possible ascertainment bias toward severe cases.
2. No natural-history or registry data. Adult trajectories, life expectancy, and validated quality-of-life metrics are undocumented.
3. Tumor risk unresolved. SETD2 is a tumor suppressor and a constitutional multi-tumor case exists, but LLS-cohort cancer risk and the value of surveillance are unknown.
4. Mechanistic attribution. The relative contribution of the chromatin (H3K36me3) versus cytoskeletal (α-TubK40me3) arm to specific human phenotypes has not been dissected in patients.
5. Intra-LLS genotype–phenotype. Beyond the codon-1740 dichotomy, predictors of severity within LLS (truncation position, residual protein) are unestablished.
6. No dose-accurate mammalian LLS model. Constitutive KO is lethal; a heterozygous/knock-in model co-recapitulating overgrowth and behavior is lacking.
7. Overgrowth driver. The GH/STAT5b/IGF-1 finding is from a single case and not generalized.

Proposed Follow-up Experiments / Actions

1. Establish an international LLS registry to aggregate genotype, phenotype frequencies, growth trajectories, tumor events, and QoL — powering robust penetrance/expressivity and prognosis estimates.
2. Generate a dose-accurate mouse model (Setd2 heterozygous LoF or patient-specific knock-in) and phenotype for macrocephaly, cortical lamination, dendritic morphology, and behavior.
3. Refine and standardize the SETD2 EpiSign episignature for VUS reclassification and test whether episignature features distinguish LLS from RAPAS/MRD70 or correlate with severity.
4. Prospective tumor-surveillance pilot in constitutional SETD2-variant carriers to quantify malignancy risk and evaluate whether imaging/biochemical screening is justified.
5. Dissect the two mechanistic arms using separation-of-function alleles in patient iPSC-derived cortical organoids/neurons to map which clinical features track with each activity.
6. Interrogate the GH/STAT5b/IGF-1 axis across multiple patients (serum IGF-1; GH-stimulated STAT5b phosphorylation) to test generalizability and druggability of the overgrowth driver.
7. Systematic genotype–phenotype meta-analysis of all published SETD2 variants (LLS vs. MRD70 vs. RAPAS) to build a mechanism-aware variant-interpretation framework.

Consensus Answer

Luscan-Lumish syndrome (MONDO:0014916; OMIM #616831) is an ultra-rare, autosomal-dominant, near-universally de novo overgrowth and neurodevelopmental disorder caused by heterozygous loss-of-function variants in SETD2, the sole somatic H3K36 trimethyltransferase. SETD2 haploinsufficiency reduces two methyl marks — histone H3K36me3 (transcriptional fidelity, splicing, DNA repair) and α-tubulin K40me3 (neuronal migration and mitotic-spindle integrity) — producing postnatal overgrowth, macrocephaly, obesity, intellectual disability (~83%), autism (~89%), and behavioral difficulties (~100%). Diagnosis is molecular (trio WES/WGS or overgrowth-ID panels plus a SETD2 DNA-methylation episignature), and management is entirely supportive and multidisciplinary because no disease-specific or curative therapy exists.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.